首页|五子衍宗丸治疗少弱精子症的研究进展

五子衍宗丸治疗少弱精子症的研究进展

Research Progress on Wuzi Yanzong Pill in the Treatment of Oligoasthenospermia

扫码查看
目的 探讨五子衍宗丸在治疗少弱精子症(OA)的临床效果和作用机制.方法 综述近3年来五子衍宗丸治疗少弱精子症的最新研究进展,包括临床疗效、作用机制及药理学研究.结果 五子衍宗丸可通过多靶点、多途径改善精子质量和数量.主要机制包括抑制氧化应激和细胞凋亡、调节内分泌功能、保护血睾屏障、改善线粒体功能等.此外,五子衍宗丸还可能通过调节肠道菌群、影响基因表达等途径发挥作用.临床研究证实了五子衍宗丸对少弱精子症患者的治疗效果,并探讨了其与其他治疗方法的联合应用的疗效.结论 五子衍宗丸在治疗少弱精子症方面显示出良好的临床效果,但其确切作用机制和临床应用策略仍需进一步深入研究.
Objective Oligoasthenospermia(OA)is a prevalent cause of male infertility,significantly impairing fertility and life quality.The traditional Chinese medicine formula,Wuzi Yanzong Pill,has demonstrated promising efficacy in treating this condition.This article explores the clinical efficacy and mechanism of action of Wuzhi Yanzong Pill in the treatment of oligoasthenozoospermia.Methods This article reviews the latest research progress on the treatment of oligoasthenozoospermia with Wuzhi Yanzong Pill in the past three years,encompassing its clinical effectiveness,mechanisms of action,and pharmacological investigations.Result Studies have shown that Wuzi Yanzong Pill enhances sperm quality and quantity through various targets and pathways.It is primarily achieved by reducing oxidative stress and cellular apoptosis,regulating endocrine functions,protecting the blood-testis barrier,and boosting mitochondrial function.Additionally,the pill is found to influence gut microbiota and affect gene expression.Clinical research supports the therapeutic benefits of Wuzi Yanzong Pill in individuals with oligoasthenospermia and examines its synergistic use with other treatments.Conclusion Wuzhi Yanzong Pill has shown good clinical efficacy in the treatment of oligoasthenozoospermia.However,more comprehensive research is needed to fully understand its mechanisms and refine its clinical application strategies.

Wuzi Yanzong PillOligoasthenospermiaMale InfertilitySperm QualitySperm VitalitySperm Count

谭天阳、唐田、刘柘君、白雪

展开 >

中国中医科学院西苑医院康复医学科,北京 100091

中国科学院北京基因组研究所,北京 100101

首都医科大学中医药学院,北京 100069

中国中医科学院医学实验中心,北京市中医药防治重大疾病基础研究重点实验室,北京 100700

展开 >

五子衍宗丸 少弱精子症 男性不育 精子质量 精子活力 精子数量

2024

中国药物警戒
国家药品监督管理局药品评价中心(国家药品不良反应监测中心)

中国药物警戒

CSTPCD
影响因子:1.105
ISSN:1672-8629
年,卷(期):2024.21(11)